Long COVID: Symptoms, Mechanisms, and Treatment Options

What Is Long COVID?

Long COVID describes a constellation of symptoms that persist or develop after an acute SARS-CoV-2 infection. The World Health Organization defines it as symptoms continuing for at least 3 months after infection onset, lasting at least 2 months, and not explained by an alternative diagnosis. The U.S. Centers for Disease Control and Prevention uses a broader 4-week threshold ^[1].

The condition goes by several names: long COVID, long-haul COVID, post-COVID syndrome, post-acute sequelae of SARS-CoV-2 (PASC), and post-COVID condition. Regardless of the label, the experience is consistent: people who expected to recover from their infection within a week or two find themselves dealing with debilitating symptoms for months or years.

Long COVID can follow any severity of acute infection. Some of the most persistent cases occur in people whose initial illness was relatively mild, people who were never hospitalized and may have tested only mildly symptomatic. This makes it clear that long COVID is not simply about damage from a severe infection. Something else is going on ^[2].

How Common Is Long COVID?

Prevalence estimates vary widely depending on the definition used, the population studied, and the time period. A 2022 meta-analysis estimated that approximately 43% of people with COVID-19 experienced at least one long-term symptom, though many of these resolved within a few months ^[3].

More conservative estimates, focusing on persistent and functionally limiting symptoms, suggest 10-20% of infected individuals develop meaningful long COVID. A 2023 analysis estimated roughly 65 million people worldwide have been affected. Vaccination appears to reduce, but not eliminate, the risk. Some studies show a 50% risk reduction in vaccinated individuals; others show a smaller effect ^[4].

Women, people aged 35-69, those with pre-existing autoimmune conditions, and those who experienced more severe acute infections are at higher risk. Reinfection also appears to increase cumulative long COVID risk.

Common Symptoms

Long COVID is not a single disease but a syndrome with multiple subtypes. More than 200 symptoms have been reported across nearly every organ system. Here are the most common and clinically significant ones.

Fatigue

Not ordinary tiredness. Long COVID fatigue is often described as a profound, bone-deep exhaustion that does not improve with rest. It can be disabling, preventing people from working, exercising, or managing basic daily activities. In surveys, it is the single most commonly reported symptom, affecting 50-80% of long COVID patients ^[5].

Post-Exertional Malaise (PEM)

PEM is a hallmark feature. It refers to a worsening of symptoms after physical, cognitive, or emotional exertion that would have been well-tolerated before illness. The crash may be delayed by 24-72 hours and can last days or weeks. PEM is also a defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and its presence in long COVID suggests shared underlying mechanisms ^[6].

If you have PEM, pushing through symptoms typically makes things worse, not better. Activity pacing, where you stay within your “energy envelope” and avoid triggering crashes, is a critical management strategy.

Brain Fog and Cognitive Dysfunction

Cognitive complaints are reported by 50-70% of long COVID patients. These include difficulty concentrating, short-term memory problems, slow processing speed, and word-finding difficulties. Neuropsychological testing often confirms objective impairment. Neuroimaging studies have shown reduced cortical thickness, changes in white matter, and decreased glucose metabolism in affected brain regions ^[7].

The cognitive impact can be significant. Some studies have estimated the equivalent of a 3-7 point drop in IQ scores among long COVID patients with persistent brain fog. For many people, this translates into real-world difficulty managing work responsibilities, following conversations, or reading at their previous level. The good news is that cognitive symptoms do improve over time for many patients, though recovery can be slow.

Shortness of Breath and Chest Pain

Dyspnea (shortness of breath) persists in many patients even when standard pulmonary function tests appear normal. This disconnect may reflect small airway disease, diaphragm dysfunction, or autonomic dysregulation of breathing patterns. Chest tightness, chest pain, and palpitations are also common and can overlap with cardiac involvement or costochondritis.

Anyone with persistent chest pain after COVID should have a cardiac workup, including an echocardiogram and potentially a cardiac MRI. Studies have found evidence of myocardial inflammation in a subset of long COVID patients, even those with mild initial infections. While most cases resolve, identifying cardiac involvement early matters for both treatment and activity guidance.

Dysautonomia and POTS

Autonomic nervous system dysfunction is one of the most debilitating aspects of long COVID. Postural orthostatic tachycardia syndrome (POTS), where heart rate increases excessively upon standing, is frequently diagnosed in long COVID patients who had no prior history. Symptoms include dizziness, lightheadedness, rapid heartbeat, exercise intolerance, and fainting ^[8].

Other autonomic symptoms include temperature dysregulation, GI motility issues, and abnormal sweating. Tilt table testing or an active standing test can help with diagnosis.

Joint and Muscle Pain

Widespread pain, joint aches, and myalgia are reported by 20-30% of long COVID patients. This can mimic fibromyalgia and may involve central sensitization, where the nervous system amplifies pain signals.

Neuropathy

Peripheral neuropathy, including small fiber neuropathy, has been documented in long COVID. Symptoms include tingling, numbness, burning sensations (often in the hands and feet), and temperature sensitivity. Skin biopsies showing reduced intraepidermal nerve fiber density confirm small fiber involvement in some patients ^[9].

Sleep Disruption

Insomnia, unrefreshing sleep, and altered sleep architecture are common. Some patients report hypersomnia (sleeping excessively but never feeling rested). Disrupted sleep compounds fatigue, brain fog, and mood disturbance, creating a vicious cycle.

What Is Causing Long COVID? Proposed Mechanisms

Researchers have identified several plausible (and likely overlapping) mechanisms. It is probable that long COVID is not one disease but several, driven by different mechanisms in different people.

Viral Persistence

Multiple studies have detected SARS-CoV-2 viral proteins and RNA in tissues (gut, brain, lymph nodes) months after the acute infection has cleared from the respiratory tract. The virus, or viral fragments, may persist in reservoir sites, driving ongoing immune activation and inflammation. Gut biopsies have found viral antigen in tissue up to 7 months post-infection in some patients ^[10].

Autoimmunity

SARS-CoV-2 infection can trigger the production of autoantibodies, antibodies that mistakenly target the body’s own tissues. Studies have found autoantibodies targeting blood vessels, the nervous system, connective tissue, and various organs in long COVID patients. This autoimmune activation may explain why some symptoms resemble established autoimmune diseases ^[11].

Microclots and Endothelial Damage

One of the more striking findings in long COVID research is the presence of abnormal fibrin amyloid microclots in the blood. These tiny, dense clots resist normal breakdown and may impair microcirculation, reducing oxygen and nutrient delivery to tissues. Endothelial dysfunction (damage to blood vessel linings) compounds this problem. This mechanism could explain the widespread, multi-organ nature of symptoms ^[12].

Mitochondrial Dysfunction

Mitochondria, the energy-producing organelles in cells, appear to be impaired in long COVID. Studies have shown reduced mitochondrial membrane potential, altered oxidative phosphorylation, and decreased ATP production in immune cells and muscle tissue from long COVID patients. If your cells cannot produce energy efficiently, the result is exactly what patients describe: crushing fatigue and exercise intolerance ^[13].

Microbiome Disruption

COVID-19 is associated with significant changes to the gut microbiome, including reduced diversity and depletion of beneficial bacteria. These alterations persist in long COVID patients and correlate with symptom severity. Given the gut’s role in immune regulation, neurotransmitter production, and systemic inflammation, microbiome disruption may be both a consequence and a driver of ongoing symptoms ^[14].

Diagnosis

There is currently no definitive diagnostic test for long COVID. Diagnosis is clinical, based on a history of confirmed or suspected SARS-CoV-2 infection followed by persistent symptoms that are not better explained by another condition.

Standard lab work (CBC, metabolic panel, thyroid, inflammatory markers) is often normal, which can be frustrating for patients and misleading for clinicians. More specialized testing may reveal abnormalities:

• Tilt table test or active standing test for POTS/dysautonomia
• Cardiopulmonary exercise testing (CPET) for objective exercise intolerance
• Skin biopsy for small fiber neuropathy
• Echocardiogram and cardiac MRI for cardiac involvement
• Neurocognitive testing for cognitive impairment
• Cytokine panels and immune cell subtyping (available in research settings)

The exclusion-based nature of diagnosis means it is important to rule out thyroid disease, anemia, cardiac conditions, pulmonary embolism, and other treatable causes that can present with similar symptoms.

One frustration many patients face: being told their labs are “normal” and therefore nothing is wrong. Standard blood work is designed to detect common diseases, not the kind of immune dysregulation, microclotting, or mitochondrial impairment that may underlie long COVID. Normal labs do not mean you are not sick. They may simply mean the right tests have not been ordered yet, or that the available tests are not sensitive enough to capture the dysfunction.

Conventional Treatment Approaches

Symptom Management

In the absence of a cure, treatment is currently symptom-directed. This may include medications for pain, sleep, mood, and autonomic dysfunction. Beta-blockers (propranolol), ivabradine, midodrine, and fludrocortisone are commonly used for POTS. Antihistamines and mast cell stabilizers can help when mast cell activation is a factor ^[15].

Pacing and Energy Management

For patients with PEM, pacing is not optional. It is therapeutic. The goal is to identify your activity threshold (physical, cognitive, and emotional) and stay within it consistently. Heart rate monitoring can help: many patients find that keeping their heart rate below a certain threshold (often 60-70% of age-predicted maximum) prevents crashes. This approach is borrowed from ME/CFS management and is supported by expert consensus ^[16].

Graded exercise therapy (GET), which involves progressively increasing activity levels, is not recommended for patients with PEM and can cause significant harm. This is an important distinction from standard deconditioning, where graduated exercise is appropriate.

Rehabilitation

Pulmonary rehabilitation, cognitive rehabilitation, and occupational therapy can all play a role for selected patients. The key is that rehabilitation programs must be adapted to account for PEM. Cookie-cutter rehab programs that push patients to increase activity without monitoring for PEM can do more harm than good.

Emerging and Investigational Treatments

Research is moving quickly. Several promising approaches are under investigation, though none have received regulatory approval specifically for long COVID. What follows is a summary of current evidence, not a treatment recommendation.

Low-Dose Naltrexone (LDN)

Naltrexone at low doses (1-4.5 mg, far below the standard 50 mg used for addiction) has immunomodulatory and anti-inflammatory properties. It appears to work by transiently blocking opioid receptors, leading to an upregulation of endorphins and a modulation of microglial (brain immune cell) activation. Observational studies and small trials in long COVID patients have shown improvements in fatigue, pain, and cognitive function. Larger trials are underway ^[17].

Hyperbaric Oxygen Therapy (HBOT)

HBOT involves breathing pure oxygen in a pressurized chamber. A randomized controlled trial from Israel showed significant improvements in cognitive function, fatigue, sleep, and pain in long COVID patients after 40 sessions. The proposed mechanism involves enhanced oxygen delivery, angiogenesis, and anti-inflammatory effects. Access remains limited and costly, and the optimal protocol is not yet standardized ^[18].

NAD+ IV Therapy

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential for mitochondrial energy production. Intravenous NAD+ administration aims to directly support impaired cellular energy metabolism. Clinical evidence is limited to case series and anecdotal reports, but the biological rationale is sound given the mitochondrial dysfunction observed in long COVID. Oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are more accessible alternatives being studied ^[19].

Stellate Ganglion Block (SGB)

SGB is an injection of local anesthetic into the stellate ganglion, a cluster of sympathetic nerves in the neck. Originally used for complex regional pain syndrome and PTSD, it has been explored for long COVID, particularly for symptoms of autonomic dysfunction. Early case series reported improvements in brain fog, fatigue, and dysautonomia. The theory is that SGB “resets” a dysfunctional sympathetic nervous system. Evidence is still preliminary ^[20].

Anticoagulation Protocols

Based on the microclot hypothesis, some clinicians have used anticoagulant and antiplatelet therapies to address microvascular clotting. The “triple anticoagulation” approach (typically involving a combination of anticoagulants, antiplatelets, and sometimes fibrinolytics) has been reported anecdotally to improve symptoms in some patients. This remains controversial and carries bleeding risks. Clinical trials are needed to establish safety and efficacy ^[21].

GLP-1 Receptor Agonists

Intriguing preliminary data suggest that GLP-1 receptor agonists (such as semaglutide), originally developed for diabetes and obesity, may reduce long COVID risk or improve symptoms. A large retrospective study found that patients on GLP-1 agonists had significantly lower rates of long COVID. The proposed mechanism involves anti-inflammatory effects and improved endothelial function. This is an active area of investigation ^[22].

Overlap with ME/CFS

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, multi-system disease characterized by profound fatigue, PEM, unrefreshing sleep, cognitive impairment, and orthostatic intolerance. If this sounds familiar, it should. The symptom overlap between long COVID and ME/CFS is substantial.

An estimated 50% or more of long COVID patients meet diagnostic criteria for ME/CFS. This has been both a validation and a challenge: validation because it gives long COVID patients access to decades of ME/CFS research and management strategies, and a challenge because ME/CFS itself remains poorly understood and significantly underfunded ^[23].

The ME/CFS community’s hard-won insights about pacing, the dangers of graded exercise in the presence of PEM, and the biological basis of the illness have been invaluable for long COVID patients and clinicians.

Mast Cell Activation Syndrome (MCAS) Connection

Some long COVID patients develop symptoms consistent with mast cell activation syndrome: flushing, hives, GI disturbance, rapid heart rate, food and chemical sensitivities, and episodes triggered by heat, stress, or certain foods. Mast cells are immune cells that release histamine and other inflammatory mediators. When they become hyperactivated, the result is widespread, fluctuating, multi-system symptoms.

Mast cell stabilizers (cromolyn sodium, ketotifen) and H1/H2 antihistamine combinations have provided relief for some long COVID patients with MCAS-type presentations. This is an area where clinical pattern recognition is ahead of published research ^[24].

POTS and Long COVID

Postural orthostatic tachycardia syndrome has emerged as one of the most common diagnosable conditions within the long COVID spectrum. Studies suggest that 30-60% of long COVID patients with persistent symptoms meet criteria for POTS or orthostatic intolerance.

Management includes increased fluid intake (2-3 liters daily), electrolyte supplementation (especially sodium), compression garments, and gradual reclined exercise programs specifically designed for POTS patients. Medications like propranolol, ivabradine, midodrine, and fludrocortisone are used as needed ^[25].

Finding a Knowledgeable Provider

One of the greatest frustrations for long COVID patients is the difficulty of finding clinicians who understand the condition. Many patients report being dismissed, told their symptoms are anxiety, or offered treatments (like aggressive exercise programs) that worsen their condition.

Look for providers who:

• Have specific experience with post-infectious syndromes, ME/CFS, or dysautonomia
• Take post-exertional malaise seriously and do not recommend pushing through symptoms
• Are willing to order specialized testing (tilt table, CPET, small fiber neuropathy biopsy)
• Stay current with rapidly evolving long COVID research
• Take a systematic, multi-system approach rather than treating symptoms in isolation

Long COVID clinics affiliated with academic medical centers, ME/CFS specialty clinics, and integrative medicine practices with an interest in post-viral illness are good places to start. Patient advocacy organizations like Body Politic, Survivor Corps, and the Long COVID Alliance maintain provider directories.

Prognosis and Recovery Timeline

Recovery from long COVID is possible, but the timeline varies enormously. Some people improve steadily over 6-12 months. Others remain symptomatic for years. A subset appears to develop a chronic illness indistinguishable from ME/CFS.

Factors associated with better outcomes include milder initial symptom burden, absence of PEM, younger age, and access to early supportive care. Reinfection can cause relapse or worsening in some patients.

The honest answer is that we do not yet have reliable predictors of who will recover fully and who will not. What we do know is that appropriate management (pacing, targeted symptom treatment, avoiding harm from inappropriate exercise programs) can prevent deterioration and improve quality of life while research continues to advance toward disease-modifying treatments ^[26].

The Bottom Line

Long COVID is a real, biologically based condition affecting millions of people. It is not anxiety, deconditioning, or a lack of willpower. The research is evolving rapidly, and there is genuine reason for cautious optimism as new mechanisms are identified and treatments are tested.

If you are living with long COVID, the most important steps are: find a provider who understands post-infectious illness, learn to pace your activity to avoid PEM, address treatable symptoms (POTS, sleep, pain), and stay connected to reliable sources of information as the evidence base grows.

Preventing Long COVID

While no strategy guarantees protection against long COVID, several factors appear to lower risk. Vaccination remains the most studied preventive measure. A 2023 meta-analysis found that individuals who were vaccinated before their breakthrough infection had roughly 40-50% lower odds of developing long COVID compared to unvaccinated individuals.

Early treatment of acute COVID (particularly with Paxlovid in the first 5 days of symptoms) may also reduce long COVID risk, though the data are mixed. Some retrospective studies show significant benefit; others are less conclusive. Maintaining good metabolic health, managing blood sugar, getting adequate sleep, and addressing chronic inflammation before infection may also help, though these are harder to study in controlled settings.

Avoiding reinfection is another practical consideration. Each infection appears to carry its own risk of long COVID, and there is evidence that repeated infections may have cumulative effects on vascular and immune health. Standard precautions (air filtration, ventilation, masking in high-risk settings) remain sensible strategies, especially for those who have already experienced long COVID once.

Frequently Asked Questions

Is there an approved treatment that cures long COVID?

No. According to this guide, there are currently no disease-modifying treatments approved for long COVID, and there is no definitive diagnostic test. What the page presents is a summary of current evidence rather than a treatment recommendation, and the symptom medications used (such as beta-blockers, ivabradine, midodrine, and fludrocortisone for POTS) are approved for other conditions and used off-label.

What does the evidence show for hyperbaric oxygen therapy (HBOT)?

A single randomized controlled trial from Israel, using a protocol of 40 sessions, showed significant improvements in cognitive function, fatigue, sleep, and pain. The guide describes HBOT as costly, with access that remains limited, and notes the optimal protocol is not yet standardized. HBOT is FDA-approved for other conditions and used off-label for long COVID.

How strong is the evidence for low-dose naltrexone (LDN) and NAD+ IV therapy?

The evidence is preliminary for both. LDN, dosed at 1 to 4.5 mg rather than the standard 50 mg, is supported by observational studies and small trials showing improvements in fatigue, pain, and cognition, with larger trials underway. NAD+ IV therapy is supported only by case series and anecdotal reports, and the guide notes clinical evidence is limited. Neither is approved for long COVID.

How long does it take to recover from long COVID?

The guide states recovery is possible but the timeline varies enormously. Some people improve steadily over 6 to 12 months, others remain symptomatic for years, and a subset appears to develop a chronic illness indistinguishable from ME/CFS. There are not yet reliable predictors of who will recover fully and who will not.

Are these treatments safe, and do any carry risks?

Safety details vary by treatment and are not fully described for the emerging options. The guide specifically flags that triple anticoagulation protocols carry bleeding risks and remain controversial, with clinical trials still needed. It also cautions that standard rehabilitation and graded exercise therapy can do more harm than good if not adapted to account for post-exertional malaise.

Can anything reduce the risk of getting long COVID in the first place?

Vaccination is associated with 40 to 50% lower odds of long COVID, though the guide notes it does not guarantee protection. Separately, a large retrospective study found significantly lower rates of long COVID among people taking GLP-1 receptor agonists such as semaglutide, which the page describes as an active area of investigation rather than an established preventive.

References

1. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9
2. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
3. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593-1607. doi:10.1093/infdis/jiac136
4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
5. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19. JAMA Netw Open. 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417
6. Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG. Chronic fatigue and postexertional malaise in people living with long COVID. Phys Ther. 2022;102(4):pzac005. doi:10.1093/ptj/pzac005
7. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707. doi:10.1038/s41586-022-04569-5
8. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205-211. doi:10.1007/s12026-021-09185-5
9. Abrams RMC, Simpson DM, Navis A, et al. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. 2022;65(4):440-443. doi:10.1002/mus.27458
10. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487-e490. doi:10.1093/cid/ciac722
11. Chang SE, Feng A, Mena-Palomo I, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi:10.1038/s41467-021-25509-3
12. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi:10.1186/s12933-021-01359-7
13. Guarnieri JW, Dybas JM, Fazelinia H, et al. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med. 2023;15(708):eabq1533. doi:10.1126/scitranslmed.abq1533
14. Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-552. doi:10.1136/gutjnl-2021-325989
15. Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022;70(1):61-67. doi:10.1136/jim-2021-002051
16. Davenport TE, Stevens SR, Stevens J, Snell CR, Van Ness JM. Lessons from myalgic encephalomyelitis/chronic fatigue syndrome for long COVID: postexertional symptom exacerbation is an abnormal response to exercise/activity. Arch Phys Med Rehabil. 2023;104(12):2149-2151. doi:10.1016/j.apmr.2023.05.016
17. O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort. Int Immunopharmacol. 2022;110:109044. doi:10.1016/j.intimp.2022.109044
18. Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252. doi:10.1038/s41598-022-15565-0
19. Braidy N, Berg J, Clement J, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases. Antioxid Redox Signal. 2019;30(2):251-294. doi:10.1089/ars.2017.7269
20. Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of long COVID: a case series. J Neuroimmunol. 2022;362:577784. doi:10.1016/j.jneuroim.2021.577784
21. Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19. Cardiovasc Diabetol. 2022;21(1):148. doi:10.1186/s12933-022-01579-9
22. Zisis SN, Durber CM, Mervosh NL, et al. GLP-1 receptor agonists and long COVID: a target for prevention and treatment? Trends Endocrinol Metab. 2024;35(5):371-374. doi:10.1016/j.tem.2024.02.015
23. Bonilla H, Quach TC, Tiwari A, et al. Myalgic encephalomyelitis/chronic fatigue syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC). Front Neurol. 2023;14:1109217. doi:10.3389/fneur.2023.1109217
24. Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332. doi:10.1016/j.ijid.2020.09.016
25. Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021;31(3):365-368. doi:10.1007/s10286-021-00798-2
26. Tran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13(1):1812. doi:10.1038/s41467-022-29513-z
27. Mitochondrial Health: Why Cellular Energy Matters
28. Your Gut Microbiome: A Practical Guide
29. Understanding Dysautonomia and POTS
30. The Anti-Inflammatory Diet: What the Evidence Says
31. NAD+ and Cellular Health: What You Need to Know